Trial Profile
A prospective, multicentre postmarketing surveillance to monitor safety associated with usage of Simponi® (golimumab injection 50mg) in Indian subjects with Rheumatoid Arthritis as per locally approved prescribing information
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Sep 2016 New trial record